In this presentation, Maalouf Hoteit, MD, examines the current state of hepatocellular carcinoma diagnosis, treatment and prevention from the perspective that early screening and treatment of hepatitis C and early treatment of liver cancer holds the greatest promise patients at risk for the disease. Includes a discussion of the PD-1 inhibitor nivolumab, the latest addition to the armamentarium for advanced HCC.
Related Links
Published
August 4, 2016
Created by
BROADCASTMED